Tom Powles
@tompowles1
Followers
13K
Following
366
Media
642
Statuses
2K
Interested in Urology Cancers, biomarkers and drug development.
Joined December 2019
Updated Uromigos Score in cisplatin eligible MIBC bladder cancer #uromigosLive Perioperative durva with neoadjuvant gem/cis scored best. Perioperative EVP was close behind despite little data in this population. Approaches not including neoadjuvant IO scored less well @OncoAlert
0
4
8
Updated Uromigos Score for metastatic urothelial cancer. EVP(3/3) & DVT(2.5/3) both strongly recommended.Alternatives score much less well. Shorter follow up, the need for HER2 testing,⬇️ global experience & ⬇️ CRs may account for the slightly lower score of DVT vs EVP @OncoAlert
1
4
8
Updated Uromigos Score in cisplatin ineligible MIBC bladder cancer #uromigosLive -EVP scored 2.9/3. Cystectomy/adjuvant IO including ctDNA risk adapted approaches scored lower(1.5-1.9) & are no longer strongly recommended.Initial EVP rather than surgery is now standard @OncoAlert
0
6
14
Treatment for IMDC good risk renal cancer has become complex. @BradMcG04 tells us that the biology doesn’t track IMDC score and in good risk disease nothing is clearly better than sunitinib. So what is the right treatment? @OncoAlert @DrChoueiri #UromigosLive
1
3
15
Congratulations to Zeynep Ozay @ziremozay from Huntsman Cancer Institute - Utah 🏔️ ⛰️🏔️ who is our Uromigos golden ticket 🥇 🎫 🥇 winner #uromigosLive Below is her winning T shirt design. See you on Friday in Nashville @OncoAlert
3
13
40
There’s not a Friend like the lowly Jesus: No, not one! no, not one! None else could heal all our souls’ diseases: No, not one! no, not one! Jesus knows all about our struggles; He will guide ’til the day is done: There’s not a Friend like the
2
0
23
After the success of Disitamab Vedotin plus toripalimab in bladder cancer #ESMO25 we asked what other randomised trial are ongoing in China 🇨🇳 ? In this Uromigos Short Dr Yige Bao describes a number of new RIII studies #uromigoslive @oncoalert
1
8
23
Disitamab Vedotin plus toripalimab was developed exclusively in China. Here Dr Yige Bao describes 4 other ADCs in phase III, also in China. Some of these are likely to be globally impactful. The video peers into the future of UC. It’s worth a look #uromigoslive @oncoalert
After the success of Disitamab Vedotin plus toripalimab in bladder cancer #ESMO25 we asked what other randomised trial are ongoing in China 🇨🇳 ? In this Uromigos Short Dr Yige Bao describes a number of new RIII studies #uromigoslive @oncoalert
1
20
80
In this video @VincentWenxinXu gives an overview on the most promising biomarker to date in kidney cancer (KIM1). In the CAPLPSO clear cell trial more KIM-1 ⬇️ occurred with durva/treme vs Durva alone. Could KIM1 be better surrogate of OS than radiology. @DrChoueiri @OncoAlert
KIM-1 is the hottest biomarker in kidney cancer. Some call it the ctDNA of this disease. @VincentWenxinXu leads the research in this area. In this video he defines positivity & tells us what that means. Is it ready for clinical use VIncent ? @OncoAlert @DrChoueiri #UromigosLive
1
18
41
KIM-1 is the hottest biomarker in kidney cancer. Some call it the ctDNA of this disease. @VincentWenxinXu leads the research in this area. In this video he defines positivity & tells us what that means. Is it ready for clinical use VIncent ? @OncoAlert @DrChoueiri #UromigosLive
2
13
30
Variant histologies in UC are under exolored. @Dr_Aggen breaks this down into key subgroups and outlines optimal treatment approaches. How important the degree/percentage of differentiation away from pure urothelial?
Variant histologies in bladder cancer can be confusing. Here @Dr_Aggen gives a fabulous overview of key subgroups such as micropapillary (high HER2), plasmacytoid (E-cadherin loss) and adenocarcinoma (treat with FOLFOX). All you wanted to know but were afraid to ask!! @OncoAlert
1
10
37
Enfortumb vedotin is an integral componenet of #bladder cancer mgmt. In this #UromigosShorts video, @AmandaNizamMD @ClevelandClinic discusses nuances of EV toxicity recognition and management. @OncoAlert
1
9
33
Excellent talk @bergsa83 on the very important topic of upper tract urothelial cancer. Still need to find therapeutic strategies targeting the distinct biology in this disease #PrecisionMedicine one barrier is the lack of faithful UTUC animal models to test these strategies.
Upper tact urothelial cancer has distinct biology & clinical management compared to bladder cancer. Here @bergsa83 addresses the neoadjuvant vs adjuvant chemo debate and whether PD-1s are potentially less active. The role of FGFR. Also, why not give Perioperative EVP? @OncoAlert
0
2
9
Alfonso Gomez @Uro_Oncologist describes how moving FGFR inhibition earlier into non-muscle invasive urothelial cancer (where DNA FGFR alteration are more common) is ongoing. New devices such as TAR210 is a novel way of delivering intravesicle erdafirinib @OncoAlert #UromigosLive
🚀 New kids on the block: FGFR3-selective inhibitors and novel delivery devices. 💧🧠💪 Safer, smarter, stronger? @Uro_Oncologist discusses this in a #UromigosShorts video. @OncoAlert
0
11
31
Upper tact urothelial cancer has distinct biology & clinical management compared to bladder cancer. Here @bergsa83 addresses the neoadjuvant vs adjuvant chemo debate and whether PD-1s are potentially less active. The role of FGFR. Also, why not give Perioperative EVP? @OncoAlert
Upper Tract Urothelial Cancer (UTUC) is an important but less well studied urothelial cancer. In the #UromigosShorts video below @bergsa83 from @DanaFarber_GU discusses the clinical management of these patients and ongoing clinical trials. @OncoAlert @DrChoueiri
1
7
34
The final analysis of cabozantinib plus nivolumab in 1st line clear cell renal cancer @Annals_Oncology @DrChoueiri shows consistent data over time and with other VEGF/PD-1 combinations. ‘Pick one and use it well’ remains a good approach.
3
44
121
今週は@crisuarez08 からサクラダファミリアの荘厳な写真。さすが地元民はいい場所といい時間、映える角度知ってますねー。❤️で応援お願いします。#UromigosLive! @OncoAlert
The Eurasia team 🇯🇵 🇨🇳 🇦🇺 🇳🇱 🇪🇸 🇮🇳 are now 7-0 ahead for the Uromigos cup 🏆 @MichvdHeijden getting a record 98 ♥️. The final round for Eurasia is @crisuarez08 🇪🇸 🇪🇸 🇪🇸 🇪🇸 with a little help from Gaudi. It feels hard to beat. The #UromigosLive!meeting is next week @OncoAlert
0
3
4
One of the best overviews of emerging mCRPC treatments to date by @PBarataMD . Bispecifics and ADCs are the future, alongside advances in radioligands. Despite all we have achieved in past 10 years, still a clear unmet need for mCRPC post docetaxel and ARPI, where rwOS ~12 mths
ADC & cellular therapies may transform prostate cancer. Phase 2s exist but there are 3 RIII trials as @PBarataMD states in this video. I-DXD vs docetaxel is the ADC R3. While 2 bispecifics RII (pasritamig targeting KLK-2 & Xaluritamig targeting STEAP-1) are ongoing @OncoAlert
0
9
19
Excellent discussion by @scocmem looking forward to discussing more details @Uromigos meeting Nashville Nov 7-8! @tompowles1 @brian_rini @shilpaonc @montypal @neerajaiims @OncoAlert @MichvdHeijden @DrRanaMcKay @crisuarez08 @DrRosenbergMSK @alantanmd @AmandaNizamMD @Dr_Aggen
Randomized trials testing ctDNA and HER-2 biomarkers in bladder cancer both delivered positive results with OS #ESMO25 . Here @scocmem described how these and other biomarkers are changing bladder cancer. @PGrivasMDPhD @OncoAlert #uromigosLive
0
7
14
Randomized trials testing ctDNA and HER-2 biomarkers in bladder cancer both delivered positive results with OS #ESMO25 . Here @scocmem described how these and other biomarkers are changing bladder cancer. @PGrivasMDPhD @OncoAlert #uromigosLive
How useful are the 4 utilised biomarkers in urothelial ca (FGFR3, ctDNA, PD-L1, HER-2). Here @scocmem addresses these issues & discussed key informing trials (IM011, DV/Toripalimab, THOR, NORSE). Will PD-L1 remain ultilzed, is HER2 IHC sufficient, is ctDNA predictive? @OncoAlert
2
12
42
#UromigosLive 2025がいよいよ11月7日、8日で開催されます。今年も #UromigosCup 参加に向けてΤシャツを作りました🤭 3人で頑張ってきます‼️ @YujiMiura5 @hiroshi_dko @Uromigos
0
6
9